Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFTAWU)

Drug Name

mRNA-2416 Drug Info

Synonyms

mRNA-OX40L

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]
Ovarian cancer	2C73	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TAX transcriptionally-activated glycoprotein 1 (OX40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[4]
RG7888	DM2SWI8	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
Amlitelimab	DMKR3BQ	Asthma	CA23	Phase 2	[6]
mRNA-2752	DMUKBI2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
MEDI6383	DM1YSMD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
SAR442970	DM3DHWE	Inflammation	1A00-CA43.1	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TAX transcriptionally-activated glycoprotein 1 (OX40)	TTBW580	TNFL4_HUMAN	Replacement	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03323398) Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Moderna Therapeutics.
4	Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
5	Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
6	OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
7	Clinical pipeline report, company report or official report of Moderna Therapeutics.
8	J Clin Oncol 33, 2015 (suppl; abstr 3056).
9	Clinical pipeline report, company report or official report of Sanofi